Payment overview · 2025
General Payments
$396.40
24 reported records · 6 companies
Healthcare provider profile · identity verified
Pratheesh Viswanathan, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LEMOYNE, PA · NPI 1588655989
Verified facts
What the public records show
CMS Open Payments records show Pratheesh Viswanathan, MD received $396.40 in general payments during 2025 across 24 reported records.
GlaxoSmithKline, LLC. accounted for 45.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $179.07 | 45.2% | 15 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $82.68 | 20.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $65.08 | 16.4% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $34.54 | 8.7% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $20.24 | 5.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.79 | 3.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $396.40 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $115.58 | 8 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $82.68 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $77.05 | 8 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $65.08 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $63.49 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $44.83 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $34.54 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $34.54 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $20.24 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.79 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 68 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 51 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
51 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
68 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 559 | 184 |
| Amlodipine Besylate | Amlodipine Besylate | 497 | 140 |
| Pantoprazole Sodium | Pantoprazole Sodium | 334 | 103 |
| Levothyroxine Sodium | Levothyroxine Sodium | 310 | 83 |
| Prednisone | Prednisone | 290 | 195 |
| Lorazepam | Lorazepam | 275 | 67 |
| Metoprolol Succinate | Metoprolol Succinate | 262 | 72 |
| Famotidine | Famotidine | 237 | 76 |
| Losartan Potassium | Losartan Potassium | 205 | 60 |
| Gabapentin | Gabapentin | 181 | 52 |
| Simvastatin | Simvastatin | 166 | 50 |
| Montelukast Sodium | Montelukast Sodium | 157 | 54 |
| Alprazolam | Alprazolam | 153 | 42 |
| Lisinopril | Lisinopril | 146 | 44 |
| Omeprazole | Omeprazole | 139 | 50 |
| Eliquis | Apixaban | 136 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 124 | 35 |
| Furosemide | Furosemide | 120 | 42 |
| Oxycodone Hcl | Oxycodone Hcl | 120 | 19 |
| Tramadol Hcl | Tramadol Hcl | 119 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 116 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 116 | 38 |
| Diclofenac Sodium | Diclofenac Sodium | 113 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 109 | 33 |
| Allopurinol | Allopurinol | 102 | 35 |
| Jardiance | Empagliflozin | 102 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 101 | 29 |
| Metformin Hcl | Metformin Hcl | 97 | 33 |
| Carvedilol | Carvedilol | 94 | 28 |
| Glimepiride | Glimepiride | 92 | 27 |
| Buspirone Hcl | Buspirone Hcl | 85 | 31 |
| Mounjaro | Tirzepatide | 85 | 21 |
| Clonazepam | Clonazepam | 83 | 17 |
| Trazodone Hcl | Trazodone Hcl | 81 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 80 | 28 |
| Potassium Chloride | Potassium Chloride | 80 | 26 |
| Breo Ellipta | Fluticasone/Vilanterol | 79 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 78 | 28 |
| Sertraline Hcl | Sertraline Hcl | 73 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 70 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 70 | 33 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 70 | 17 |
| Ozempic | Semaglutide | 68 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 67 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 66 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 62 | 18 |
| Meloxicam | Meloxicam | 61 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 59 | 16 |
| Bumetanide | Bumetanide | 58 | 18 |
| Mirtazapine | Mirtazapine | 54 | 13 |
| Baclofen | Baclofen | 53 | 18 |
| Celecoxib | Celecoxib | 52 | 19 |
| Xarelto | Rivaroxaban | 52 | suppressed |
| Pregabalin | Pregabalin | 51 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 51 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 49 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 49 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 48 | suppressed |
| Ezetimibe | Ezetimibe | 47 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 46 | 15 |
| Alendronate Sodium | Alendronate Sodium | 45 | 17 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 45 | 15 |
| Finasteride | Finasteride | 42 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 41 | 32 |
| Fenofibrate | Fenofibrate Nanocrystallized | 41 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 41 | 25 |
| Spironolactone | Spironolactone | 39 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 38 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 38 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 37 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 36 | 13 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 36 | 11 |
| Klor-Con M20 | Potassium Chloride | 34 | suppressed |
| Synthroid | Levothyroxine Sodium | 34 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 33 | 12 |
| Atenolol | Atenolol | 32 | suppressed |
| Bupropion Xl | Bupropion Hcl | 32 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Trulicity | Dulaglutide | 31 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 24 |
| Sucralfate | Sucralfate | 30 | suppressed |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Oxycontin | Oxycodone Hcl | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 26 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 25 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Dutasteride | Dutasteride | 25 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Metolazone | Metolazone | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | 13 |
| Clonidine | Clonidine | 17 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 15 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 14 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | 11 |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Nateglinide | Nateglinide | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Trimethoprim | Trimethoprim | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Admelog Solostar | Insulin Lispro | 11 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $396.40 · 24 records | GlaxoSmithKline, LLC. | ACCRUFER, AREXVY, AUSTEDO XR, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error